A recent study by Spherix Global Insights highlights the unmet need for new treatments in warm autoimmune hemolytic anemia (w-AIHA), especially beyond second-line therapies where no clear standard exists. Current treatments rely heavily on corticosteroids and rituximab, which have limitations including poor tolerance and incomplete responses. Physicians are optimistic about late-stage pipeline drugs like Sanofi's rilzabrutinib and Johnson & Johnson's niopcalimab, which could offer durable, steroid-sparing options and potentially redefine third-line treatment. These novel therapies may first establish themselves in refractory cases but could move earlier in treatment if proven effective and safe.
Recludix Pharma announced preclinical results for REX-8756, an oral STAT6 inhibitor, showing strong efficacy and safety in models of allergic asthma and dermatitis. The data, presented at two major allergy and dermatology congresses, indicate that RE...
Sanofi has stopped its Phase 3 MOBILIZE trial testing riliprubart for chronic inflammatory demyelinating polyneuropathy (CIDP) due to unlikely efficacy success, though no safety issues were found. The company will review other riliprubart studies and...
Sanofi has stopped the phase 3 MOBILIZE clinical trial of riliprubart for treating chronic inflammatory demyelinating polyneuropathy (CIDP) after an interim review showed the study is unlikely to demonstrate sufficient efficacy. No safety concerns we...
HR Tech 2026, scheduled for October 20-22 in Las Vegas, announced its agenda centered on real-world AI implementation, workforce skills, and HR transformation. The event features sessions from leaders at major companies like IFF, Lumen, and Sanofi, c...
Kymera Therapeutics has dosed the first participant in the Phase 1 clinical trial of KT-485, an oral IRAK4 degrader, marking a key milestone under its collaboration with Sanofi. This event triggered a $20 million milestone payment from Sanofi to Kyme...
